(secondQuint)A Study of Tasisulam in Treating Participants With Malignant Melanoma.

 Participants will receive a 2-hour intravenous infusion of study drug (tasisulam) once every 28 days.

 Radiological imaging scans will be performed before the first dose of study drug and then after every other treatment.

 Participants will be assessed for clinical progression at every visit and for response approximately every 56 days (every other cycle).

.

 A Study of Tasisulam in Treating Participants With Malignant Melanoma@highlight

The primary purpose of this study is to determine the objective response rate (complete and partial response) for participants who receive tasisulam after one prior systemic treatment for unresectable or metastatic melanoma.

